ADNP syndrome

Last updated
ADNP syndrome
Other namesHelsmoortel Van der Aa syndrome, HVDAS
Specialty Medical genetics, pediatrics
Symptoms Delayed development, characteristic physical features, mild to moderate intellectual disability
OnsetConception (but may be detected in early childhood)
DurationLifelong
Causes De novo mutation in the ADNP gene
Diagnostic method Genetic testing
TreatmentPhysical therapy, Occupational therapy, Speech therapy, Educational support
FrequencyUnknown as of yet – there are approximately 300 known cases

ADNP syndrome, also known as Helsmoortel-Van der Aa syndrome (HVDAS), is a non-inherited neurodevelopmental disorder caused by mutations in the activity-dependent neuroprotector homeobox (ADNP) gene. [1] [2]

Contents

The hallmark features of the syndrome are intellectual disability, global developmental delays, global motor planning delays, and autism spectrum disorder (ASD) or autistic features. Although ADNP syndrome was only identified in 2014, it is projected to be one of the most frequent single-gene causes of ASD. [3]

By June 2022, just over 275 children have been registered in the ADNP Kids Research Foundation Contact Registry. [4]

Signs and symptoms

Symptoms of ADNP syndrome are variable, but the following are typical characteristics: [5] [6] [7]

Other commonly observed traits include: [5] [6] [7]

Almost all children with ADNP syndrome have speech delay. The average age for first words has been observed to be 30 months, with a range of 7 to 72 months. [1] Some individuals studied did not develop any language skills. [1] Children with ADNP syndrome show some degree of intellectual disability. The degree can range from mild (roughly 1 in 8 children) to severe (roughly half of children). Toilet training is delayed in most children. Loss of previously acquired skills was reported in one fifth of children. [1]

The majority of children with ADNP syndrome have features of ASD, although with less severe socializing difficulties than other children with ASD. [9] During infant and toddler years, children are often reported to have a notably happy personality. [4]

Genetics

ADNP syndrome is caused by non-inherited (de novo) mutations in the ADNP gene. [10] Spanning about 40 kb of DNA, the ADNP gene maps to the chromosomal position chr20q13.13 in the human genome. [9] The protein produced from this gene helps control the activity (expression) of other genes through a process called chromatin remodeling. Chromatin is the network of DNA and protein that packages DNA into chromosomes. The structure of chromatin can be changed (remodeled) to alter how tightly DNA is packaged. [2]

Chromatin is a substance within a chromosome consisting of DNA and protein. The DNA carries the cell's genetic instructions. The major proteins in chromatin are histones, which help package the DNA in a compact form that fits in the cell nucleus. Chromatin and histones.jpg
Chromatin is a substance within a chromosome consisting of DNA and protein. The DNA carries the cell's genetic instructions. The major proteins in chromatin are histones, which help package the DNA in a compact form that fits in the cell nucleus.

By regulating gene expression, the ADNP protein is involved in many aspects of growth and development. It is particularly important for regulation of genes involved in normal brain development, and it likely controls the activity of genes that direct the development and function of other body systems. [2] [6] These changes likely explain the intellectual disability, ASD features, and other diverse signs and symptoms of ADNP syndrome. [2]

So far, only loss-of-function mutations such as stop-gain or frameshift mutations have been reported as directly related. Most, but not all mutations might give rise to a truncated protein. [9]

If neither parent is found to carry the change in the ADNP gene, the chance of having another child with ADNP syndrome is very low. However, there is a very small chance that some of the egg cells of the mother or some of the sperm cells of the father carry the change in the ADNP gene (germline mosaicism). In this case, parents who are not found to carry the same ADNP change as their child on a blood test still have a very small chance of having another child with ADNP syndrome. [4]

ADNP has been associated with abnormalities in the autophagy pathway in schizophrenia. [11] As of 2023, its precise role in the autophagy process is under active investigation. [9] [12]

Inverse comorbidity with cancer

ADNP mutations have been shown to display roles in both neurodevelopment and cancer. Equivalent mutations may result in developmental delay or in cancer depending on whether or not they are present throughout initial development. [9] A thorough meta-analysis of brains from ASD individuals revealed gene expression dysregulation and biological pathway derailments in cancer. The opposite tendency of developing one condition or another (here ASD and cancer, respectively) within a population is called inverse comorbidity . [9]

Diagnosis

The diagnosis of ADNP syndrome is established through genetic testing to identify one or more pathogenic variants on the ADNP gene.

Molecular genetic testing in a child with developmental delay or an older individual with intellectual disability typically begins with chromosomal microarray analysis. If this is not diagnostic, the next step is typically either a multigene panel or exome sequencing. Single-gene testing (sequence analysis of ADNP, followed by gene-targeted deletion/duplication analysis) may be indicated in individuals exhibiting characteristic signs of ADNP syndrome. [5]

Treatment

There is no known cure for ADPN syndrome, and so treatment is primarily symptomatic. This may include speech, occupational, and physical therapy and specialized learning programs depending on individual needs. [5] Early behavioral interventions can help children with speech delays gain self-care, social, and language skills.

Other treatments may be needed to address neuropsychiatric features, provide nutritional support, and address any ophthalmologic and cardiac findings that may co-exist. [5]

There is ongoing current research into treatments that may improve some features of the condition. In 2020, a Phase 2A clinical trial by researchers at the Seaver Autism Center at Mount Sinai Hospital suggests that low-dose ketamine may be effective in treating clinical symptoms in children diagnosed with ADNP syndrome. [13] [14]

The peptide drug davunetide or NAP, derived from the ADNP protein, has shown neuroprotective effects in preclinical trials and may be developed into a treatment for ADNP syndrome. [15]

History

The gene was first cloned in 1998, and the syndrome was first described in 2014. [16] The first ADNP Syndrome Family Conference and Scientific Symposium was held on November 3, 2019 at the UCLA campus in Los Angeles, California. [17]

See also

Related Research Articles

<span class="mw-page-title-main">Fragile X syndrome</span> X-linked dominant genetic disorder

Fragile X syndrome (FXS) is a genetic disorder characterized by mild-to-moderate intellectual disability. The average IQ in males with FXS is under 55, while about two thirds of affected females are intellectually disabled. Physical features may include a long and narrow face, large ears, flexible fingers, and large testicles. About a third of those affected have features of autism such as problems with social interactions and delayed speech. Hyperactivity is common, and seizures occur in about 10%. Males are usually more affected than females.

<span class="mw-page-title-main">Megalencephaly</span> Medical condition

Megalencephaly is a growth development disorder in which the brain is abnormally large. It is characterized by a brain with an average weight that is 2.5 standard deviations above the mean of the general population. Approximately 1 out of 50 children (2%) are said to have the characteristics of megalencephaly in the general population.

<span class="mw-page-title-main">Heritability of autism</span>

The heritability of autism is the proportion of differences in expression of autism that can be explained by genetic variation; if the heritability of a condition is high, then the condition is considered to be primarily genetic. Autism has a strong genetic basis. Although the genetics of autism are complex, autism spectrum disorder (ASD) is explained more by multigene effects than by rare mutations with large effects.

<span class="mw-page-title-main">22q13 deletion syndrome</span> Rare genetic syndrome

22q13 deletion syndrome, known as Phelan–McDermid syndrome (PMS), is a genetic disorder caused by deletions or rearrangements on the q terminal end of chromosome 22. Any abnormal genetic variation in the q13 region that presents with significant manifestations (phenotype) typical of a terminal deletion may be diagnosed as 22q13 deletion syndrome. There is disagreement among researchers as to the exact definition of 22q13 deletion syndrome. The Developmental Synaptopathies Consortium defines PMS as being caused by SHANK3 mutations, a definition that appears to exclude terminal deletions. The requirement to include SHANK3 in the definition is supported by many but not by those who first described 22q13 deletion syndrome.

<span class="mw-page-title-main">Pitt–Hopkins syndrome</span> Medical condition

Pitt–Hopkins syndrome (PTHS) is a rare genetic disorder characterized by developmental delay, epilepsy, distinctive facial features, and possible intermittent hyperventilation followed by apnea. Pitt–Hopkins syndrome can be marked by intellectual disabilities as well as problems with socializing. It is part of the clinical spectrum of Rett-like syndromes.

Autism, formally called autism spectrum disorder (ASD) or autism spectrum condition (ASC), is a neurodevelopmental disorder marked by deficits in reciprocal social communication and the presence of restricted and repetitive patterns of behavior. Other common signs include difficulties with social interaction, verbal and nonverbal communication, along with perseverative interests, stereotypic body movements, rigid routines, and hyper- or hyporeactivity to sensory input. Autism is clinically regarded as a spectrum disorder, meaning that it can manifest very differently in each person. For example, some are nonspeaking, while others have proficient spoken language. Because of this, there is wide variation in the support needs of people across the autism spectrum.

<span class="mw-page-title-main">SETBP1</span> Protein-coding gene in the species Homo sapiens

SET binding protein 1 is a protein that in humans is encoded by the SETBP1 gene.

<span class="mw-page-title-main">Sotos syndrome</span> Genetic overgrowth disorder

Sotos syndrome is a rare genetic disorder characterized by excessive physical growth during the first years of life. Excessive growth often starts in infancy and continues into the early teen years. The disorder may be accompanied by autism, mild intellectual disability, delayed motor, cognitive, and social development, hypotonia, and speech impairments. Children with Sotos syndrome tend to be large at birth and are often taller, heavier, and have relatively large skulls (macrocephaly) than is normal for their age. Signs of the disorder, which vary among individuals, include a disproportionately large skull with a slightly protrusive forehead, large hands and feet, large mandible, hypertelorism, and downslanting eyes. Clumsiness, an awkward gait, and unusual aggressiveness or irritability may also occur.

Dup15q syndrome is the common name for maternally inherited chromosome 15q11.2-q13.1 duplication syndrome. This is a genomic copy number variant that leads to a type of neurodevelopmental disorder, caused by partial duplication of the proximal long arm of Chromosome 15. This variant confers a strong risk for autism spectrum disorder, epilepsy, and intellectual disability. It is the most common genetic cause of autism, accounting for approximately 1-3% of cases. Dup15q syndrome includes both interstitial duplications and isodicentric duplications of 15q11.2-13.1.

The development of an animal model of autism is one approach researchers use to study potential causes of autism. Given the complexity of autism and its etiology, researchers often focus only on single features of autism when using animal models.

<span class="mw-page-title-main">ADNP (gene)</span> Protein-coding gene in humans

Activity-dependent neuroprotector homeobox is a protein that in humans is encoded by the ADNP gene.

Nagwa Abdel Meguid is an Egyptian geneticist and 2002 winner of the L’Oreal UNESCO Award for Women in Science for Africa and the Middle East. Her research has "identified several genetic mutations that cause common syndromes such as the fragile X syndrome and Autism".

Burnside–Butler syndrome is a name that has been applied to the effects of microdeletion of DNA sequences involving four neurodevelopmental genes. Varying developmental and psychiatric disorders have been attributed to the microdeletion; however, the great majority of people with the deletion do not have any clinical features associated with it. More studies are needed to delineate the range of clinical presentation.

<span class="mw-page-title-main">Xp11.2 duplication</span> Genetic disorder

Xp11.2 duplication is a genomic variation marked by the duplication of an X chromosome region on the short arm p at position 11.2, defined by standard karyotyping (G-banding). This gene-rich, rearrangement prone region can be further divided into three loci - Xp11.21, Xp11.22 and Xp11.23. The duplication could involve any combination of these three loci. While the length of the duplication can vary from 0.5Mb to 55 Mb, most duplications measure about 4.5Mb and typically occur in the region of 11.22-11.23. Most affected females show preferential activation of the duplicated X chromosome. Features of affected individuals vary significantly, even among members of the same family. The Xp11.2 duplication can be 'silent' - presenting no obvious symptoms in carriers - which is known from the asymptomatic parents of affected children carrying the duplication. The common symptoms include intellectual disabilities, speech delay and learning difficulties, while in rare cases, children have seizures and a recognizable brain wave pattern when assessed by EEG (electroencephalography).

<span class="mw-page-title-main">Methyl-cpg binding domain protein 5</span> Protein-coding gene in the species Homo sapiens

Methyl-CpG binding domain protein 5 is a protein that in humans is encoded by the MBD5 gene.

SYNGAP1-related intellectual disability is a monogenetic developmental and epileptic encephalopathy that affects the central nervous system. Symptoms include intellectual disability, epilepsy, autism, sensory processing deficits, hypotonia and unstable gait.

CHAMP1-associated intellectual disability syndrome, also known as autosomal dominant intellectual disability type 40, is a rare genetic disorder characterized by intellectual disabilities, developmental delays, facial dysmorphisms, and other anomalies.

Autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndrome is a rare genetic disorder which is characterized by multi-systemic symptoms primarily affecting the intellect and post-natal development.

<span class="mw-page-title-main">Severe intellectual disability-progressive spastic diplegia syndrome</span> Medical condition

Severe intellectual disability-progressive spastic diplegia syndrome is a rare novel genetic disorder characterized by severe intellectual disabilities, ataxia, craniofacial dysmorphisms, and muscle spasticity. It is a type of autosomal dominant syndromic intellectual disability.

16p11.2 deletion syndrome is a rare genetic condition caused by microdeletion on the short arm of chromosome 16. Most affected individuals experience global developmental delay and intellectual disability, as well as childhood-onset obesity. 16p11.2 deletion is estimated to account for approximately 1% of autism spectrum disorder cases.

References

  1. 1 2 3 4 Van Dijck A, Vulto-van Silfhout AT, Cappuyns E, van der Werf IM, Mancini GM, Tzschach A, et al. (February 2019). "Clinical Presentation of a Complex Neurodevelopmental Disorder Caused by Mutations in ADNP". Biological Psychiatry. 85 (4): 287–297. doi:10.1016/j.biopsych.2018.02.1173. PMC   6139063 . PMID   29724491.
  2. 1 2 3 4 "ADNP syndrome: MedlinePlus Genetics". medlineplus.gov. Retrieved 2022-09-07.
  3. ↑ "ADNP Syndrome - Symptoms, Causes, Treatment | NORD". rarediseases.org. Retrieved 2023-04-21.
  4. 1 2 3 "ADNP syndrome (Helsmoortel-VanderAa syndrome (HVDAS))" (PDF). rarechromo.org. Unique. 2022. Retrieved 2023-04-19.
  5. 1 2 3 4 5 Van Dijck A, Vandeweyer G, Kooy F (1993). "ADNP-Related Disorder". In Adam MP, Mirzaa GM, Pagon RA, Wallace SE (eds.). GeneReviews. Seattle (WA): University of Washington, Seattle. PMID   27054228.
  6. 1 2 3 Pescosolido MF, Schwede M, Johnson Harrison A, Schmidt M, Gamsiz ED, Chen WS, et al. (September 2014). "Expansion of the clinical phenotype associated with mutations in activity-dependent neuroprotective protein". Journal of Medical Genetics. 51 (9): 587–589. doi:10.1136/jmedgenet-2014-102444. PMC   4135390 . PMID   25057125.
  7. 1 2 Vandeweyer G, Helsmoortel C, Van Dijck A, Vulto-van Silfhout AT, Coe BP, Bernier R, et al. (September 2014). "The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism". American Journal of Medical Genetics. Part C, Seminars in Medical Genetics. 166C (3): 315–326. doi:10.1002/ajmg.c.31413. PMC   4195434 . PMID   25169753.
  8. ↑ Gozes I, Van Dijck A, Hacohen-Kleiman G, Grigg I, Karmon G, Giladi E, et al. (February 2017). "Premature primary tooth eruption in cognitive/motor-delayed ADNP-mutated children". Translational Psychiatry. 7 (2): e1043. doi:10.1038/tp.2017.27. PMC   5438031 . PMID   28221363.
  9. 1 2 3 4 5 6 D'Incal CP, Van Rossem KE, De Man K, Konings A, Van Dijck A, Rizzuti L, et al. (March 2023). "Chromatin remodeler Activity-Dependent Neuroprotective Protein (ADNP) contributes to syndromic autism". Clinical Epigenetics. 15 (1): 45. doi: 10.1186/s13148-023-01450-8 . PMC   10031977 . PMID   36945042.
  10. ↑ "ADNP syndrome - About the Disease - Genetic and Rare Diseases Information Center". rarediseases.info.nih.gov. Retrieved 2023-04-18.
  11. ↑ Sragovich S, Merenlender-Wagner A, Gozes I (November 2017). "ADNP Plays a Key Role in Autophagy: From Autism to Schizophrenia and Alzheimer's Disease". BioEssays. 39 (11): 1700054. doi:10.1002/bies.201700054. PMID   28940660. S2CID   21961534.
  12. ↑ Deng Z, Zhou X, Lu JH, Yue Z (December 2021). "Autophagy deficiency in neurodevelopmental disorders". Cell & Bioscience. 11 (1): 214. doi: 10.1186/s13578-021-00726-x . PMC   8684077 . PMID   34920755.
  13. ↑ Hospital, The Mount Sinai. "New study suggests ketamine may be an effective treatment for children with ADNP syndrome". medicalxpress.com. Retrieved 2022-09-07.
  14. ↑ Kolevzon, Alexander (2021-06-28). "A Phase 2A Open-Label Study Evaluating the Safety and Efficacy of Low-Dose Ketamine in Children With ADNP Syndrome". Alexander Kolevzon.
  15. ↑ Ganaiem, Maram; Gildor, Nina D.; Shazman, Shula; Karmon, Gidon; Ivashko-Pachima, Yanina; Gozes, Illana (11 September 2023). "NAP (Davunetide): The Neuroprotective ADNP Drug Candidate Penetrates Cell Nuclei Explaining Pleiotropic Mechanisms". Cells. 12 (18): 2251. doi: 10.3390/cells12182251 . PMC   10527813 . PMID   37759476.
  16. ↑ Helsmoortel C, Vulto-van Silfhout AT, Coe BP, Vandeweyer G, Rooms L, van den Ende J, et al. (April 2014). "A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP". Nature Genetics. 46 (4): 380–384. doi:10.1038/ng.2899. PMC   3990853 . PMID   24531329.
  17. ↑ "HIGHLIGHTS- ADNP Syndrome Family Conference". ADNP Kids Research Foundation. Retrieved 2023-04-19.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.